Cancer screening: Reaching the limits or terra incognita? Lessons from the EDIFICE surveys

European Journal of Cancer Prevention

Volumn 20, Issue SUPPL. 1, 2011, Pages

  Eisinger, François ^a,b,c   Roussel, Claire ^d   Morère, Jean François ^e,f   Viguier, Jérôme ^g  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Produits Roche SA   (France)

^e AVICENNE HOSPITAL   (France)

^f UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

breast cancer; cancer screening; colorectal cancer; EDIFICE surveys; France; prostate cancer

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SCREENING; COLORECTAL CANCER; FRANCE; HUMAN; MAMMOGRAPHY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

DATA COLLECTION; EARLY DETECTION OF CANCER; FEMALE; FRANCE; GOVERNMENT PROGRAMS; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; POPULATION; QUALITY IMPROVEMENT;

EID: 79551511501     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000391571.79500.ab     Document Type: Article

References (24)

1. Berman P (1978). The study of macro and microimplementation. Public Policy 26:157-184.
2. Calazel-Benque A, Viguier J, Roussel C, Pivot X, Eisinger F, Blay J-Y, et al. (2011). Organized colorectal cancer screening programmes: how to optimize efficiency in the general population. Eur J Can Prev 20 (Suppl 1): S20-S25.
3. Cameron KS (1984). The effectiveness of ineffectiveness. Research in Organizational Behavior 6:235-285.
4. Deutekom M, van Rossum LG, van Rijn AF, Laheij RJ, Fockens P, Bossuyt PM, et al. (2010). Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective. Scand J Gastroenterol 45:1345-1349.
5. Eisinger F, Beck F, Viguier J, Blay J, Coscas Y, Roussel C, et al. Increasing coverage rates for mammographic screening in France in older women - 16 years of follow-up. The Breast (in press).
6. Eisinger F (2008). Five genetic variants associated with prostate cancer. N Engl J Med 358:2740-2741. Author reply 2741.
7. Eisinger F, Fouchet R (1999). Risk management in medicine and health. Advocate for a two threshold-three-level guidelines. In: Goossens L, editor. 9th Annual Conference Risk Analysis. Rotterdam: Delft University Press; pp. 598-601.
8. Eisinger F, Dilhuidy M (2001). Lay people wiser than ad-hoc committee? Risk analysis in an interconnected world. Seattle WA USA: Society for Risk Analysis.
9. Eisinger F, Moatti JP, Beja V, Obadia Y, Alias F, Dressen C (1994). Attitudes de la population féminine française face au dépistage des cancers. Bull Cancer 81:683-690.
10. Eisinger F, Blay JY, Morere JF, Rixe O, Calazel-Benque A, Cals L, et al. (2008a). Cancer screening in France: subjects' and physicians' attitudes. Cancer Causes Control 19:431-434.
11. Eisinger F, Cals L, Calazel-Benque A, Blay JY, Coscas Y, Dolbeault S, et al. (2008b). Impact of organised programs on colorectal cancer screening. BMC Cancer 8:104.
12. Eisinger F, Blay J-Y, Pivot X, Morère J-F, Coscas Y, Calazel-Benque A, et al. (2011a). Screening for prostate cancer: growth without control. Eur J Can Prev 20 (Suppl 1): S33-S35.
13. Eisinger F, Viguier J, Blay J-Y, Morère J-F, Coscas Y, Roussel C, Pivot X (2011b). Uptake of breast cancer screening in women aged over 75 years: a controversy to come? Eur J Can Prev 20 (Suppl 1): S13-S15.
14. Esserman L, Thompson I (2010). Solving the over diagnosis dilemma. J Natl Cancer Inst 102:582-583.
15. Gutierrez-Ibarluzea I, Asua J, Latorre K (2008). Policies of screening for colorectal cancer in European countries. Int J Technol Assess Health Care 24:270-276.
16. Justice AC, Covinsky KE, Berlin JA (1999). Assessing the generalizability of prognostic information. Ann Intern Med 130:515-524.
17. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. (2001). Clinical inertia. Ann Intern Med 135:825-834.
18. Pivot X, Eisinger F, Blay J-Y, Coscas Y, Calazel-Benque A, Viguier J, et al. (2011). Mammography utilization in women aged 40-49 years: the French EDIFICE survey. Eur J Can Prev 20 (Suppl 1): S16-S19.
19. Poncet B, Colin C, Bachelot T, Jaisson-Hot I, Derain L, Magaud L, et al. (2009). Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab. Am J Clin Oncol 32:369-374.
20. Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, et al. (2010). Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem 56:237-243.
21. Sieg A, Hertel A, John MR, Luthgens K, Schmidt-Gayk H (1998). Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test. Eur J Cancer Prev 7:279-285.
22. Siegrist M, Cvetkovich G (2000). Perception of hazards: the role of social trust and knowledge. Risk Anal 20:713-719.
23. Sills D, Merton R, editors. (1991). Social science quotation. New York: Macmillan.
24. Woloshin S, Schwartz LM (2006). What's the rush? The dissemination and adoption of preliminary research results. J Natl Cancer Inst 98:372-373.